Spots Global Cancer Trial Database for malignant brain tumor
Every month we try and update this database with for malignant brain tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors | NCT00088166 | Brain Edema Brain Tumor | hCRF placebo hCRF | 18 Years - | Celtic Pharma Development Services | |
| HUMC 1612: Optune NovoTTF-200A System | NCT03128047 | High Grade Glio... Ependymoma | Optune NovoTTF-... | 5 Years - 21 Years | Hackensack Meridian Health | |
| Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | NCT01067469 | Brain Cancer Glioblastoma | Standard Dose B... Low Dose Bevaci... Lomustine | 18 Years - | M.D. Anderson Cancer Center | |
| Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa | NCT02880111 | Malignant Brain... | 6 Years - | University Hospital, Lille | ||
| National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry | NCT04351035 | Tumors, Central... Pediatric Brain... Malignant Brain... Benign Brain Tu... | Tumour resectio... | - 18 Years | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | |
| A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer | NCT02128373 | Stage IV Lung C... Malignant Brain... | Usual care computer-assist... Distress Thermo... Profile of Mood... Quality of Life... Tension-Anxiety... | 18 Years - | Case Comprehensive Cancer Center | |
| Study of Immunotoxin, MR1-1 | NCT01009866 | Supratentorial ... | MR1-1 | 18 Years - | Duke University | |
| cCeLL - Ex Vivo (Confocal Fluorescence Endomicroscopy) for Intraoperative Brain Tumor Diagnosis | NCT06098248 | Benign Brain Tu... Malignant Brain... | cCeLL - Ex vivo | 19 Years - | VPIX Medical | |
| Evaluation of the Contribution of NODDI Protocol Tractography in Brain Tumor Surgery | NCT05669326 | Malignant Brain... | NODDI TRACT | 18 Years - | GCS Ramsay Santé pour l'Enseignement et la Recherche | |
| Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | NCT02052648 | Glioblastoma Mu... Glioma Gliosarcoma Malignant Brain... | Indoximod Temozolomide Bevacizumab Stereotactic Ra... | 16 Years - | Lumos Pharma | |
| Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children | NCT02885324 | Glioblastoma Mu... Anaplastic Astr... Malignant Brain... High Grade Glio... | Cabozantinib | 2 Years - 21 Years | Indiana University | |
| DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas | NCT00805376 | Brain Cancer Central Nervous... | DNX-2401 Tumor Removal | 18 Years - | DNAtrix, Inc. | |
| ASCENT Intervention for Brain Tumor Patients | NCT06099743 | Malignant Brain... Glioma Coping Skills Distress, Emoti... | Psychosocial in... Usual supportiv... | 18 Years - | Massachusetts General Hospital | |
| Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) | NCT00615927 | Glioblastoma Gliosarcoma | Imatinib Mesyla... | 18 Years - | Duke University | |
| DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors | NCT02197169 | Glioblastoma or... | Single intratum... Interferon-gamm... | 18 Years - | DNAtrix, Inc. | |
| Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | NCT01067469 | Brain Cancer Glioblastoma | Standard Dose B... Low Dose Bevaci... Lomustine | 18 Years - | M.D. Anderson Cancer Center | |
| Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | NCT02052648 | Glioblastoma Mu... Glioma Gliosarcoma Malignant Brain... | Indoximod Temozolomide Bevacizumab Stereotactic Ra... | 16 Years - | Lumos Pharma | |
| Safety Study of Tarceva in Children With Refractory and Relapsed Malignant Brain Tumors and Newly Diagnosed Brain Stem Glioma | NCT00418327 | Malignant Brain... Brain Stem Glio... | Tarceva (Erloti... | 1 Year - 21 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM) | NCT01067469 | Brain Cancer Glioblastoma | Standard Dose B... Low Dose Bevaci... Lomustine | 18 Years - | M.D. Anderson Cancer Center | |
| Evaluation of the Contribution of NODDI Protocol Tractography in Brain Tumor Surgery | NCT05669326 | Malignant Brain... | NODDI TRACT | 18 Years - | GCS Ramsay Santé pour l'Enseignement et la Recherche | |
| Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors | NCT05169944 | Brain Cancer Malignant Brain... Recurrent Brain... Progressive Mal... Brain Tumor, Pe... Brain Tumor Adu... | Magrolimab | 3 Years - | University of California, San Francisco | |
| Study of Immunotoxin, MR1-1 | NCT01009866 | Supratentorial ... | MR1-1 | 18 Years - | Duke University | |
| Enzastaurin to Treat Recurrent Brain Tumor | NCT00108056 | Glioma | Enzastaurin (LY... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry | NCT04351035 | Tumors, Central... Pediatric Brain... Malignant Brain... Benign Brain Tu... | Tumour resectio... | - 18 Years | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | |
| NeuroPathways Intervention for Brain Tumor Patients | NCT05976490 | Malignant Brain... Glioma Coping Skills | Information and... Usual supportiv... | 18 Years - | Massachusetts General Hospital | |
| Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | NCT02502708 | Glioblastoma Mu... Glioma Gliosarcoma Malignant Brain... Ependymoma Medulloblastoma Diffuse Intrins... Primary CNS Tum... | Indoximod Temozolomide Conformal Radia... Cyclophosphamid... Etoposide | 3 Years - 21 Years | Lumos Pharma | |
| ASCENT Intervention for Brain Tumor Patients | NCT06099743 | Malignant Brain... Glioma Coping Skills Distress, Emoti... | Psychosocial in... Usual supportiv... | 18 Years - | Massachusetts General Hospital | |
| Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients | NCT05293197 | Malignant Brain... Malignant Gliom... Embryonal Tumor | SonoCloud® (9 t... | 5 Years - 17 Years | Assistance Publique - Hôpitaux de Paris | |
| Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors | NCT05169944 | Brain Cancer Malignant Brain... Recurrent Brain... Progressive Mal... Brain Tumor, Pe... Brain Tumor Adu... | Magrolimab | 3 Years - | University of California, San Francisco | |
| NeuroPathways Intervention for Brain Tumor Patients | NCT05976490 | Malignant Brain... Glioma Coping Skills | Information and... Usual supportiv... | 18 Years - | Massachusetts General Hospital | |
| Psychological Intervention For Brain Tumor Caregivers | NCT04109209 | Malignant Gliom... Anxiety Caregiver Burde... Malignant Brain... | Psychosocial In... Usual Care Grou... | 18 Years - | Massachusetts General Hospital | |
| XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors | NCT00088166 | Brain Edema Brain Tumor | hCRF placebo hCRF | 18 Years - | Celtic Pharma Development Services | |
| Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors | NCT02502708 | Glioblastoma Mu... Glioma Gliosarcoma Malignant Brain... Ependymoma Medulloblastoma Diffuse Intrins... Primary CNS Tum... | Indoximod Temozolomide Conformal Radia... Cyclophosphamid... Etoposide | 3 Years - 21 Years | Lumos Pharma |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
